BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/14/2024 9:10:00 AM | Browse: 79 | Download: 244
 |
Received |
|
2024-01-23 15:27 |
|
Peer-Review Started |
|
2024-01-23 15:27 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-02-06 07:16 |
|
Revised |
|
2024-02-13 13:58 |
|
Second Decision |
|
2024-04-16 02:44 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-04-16 07:43 |
|
Articles in Press |
|
2024-04-16 07:43 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-06-05 08:31 |
|
Publish the Manuscript Online |
|
2024-06-14 09:10 |
| ISSN |
2222-0682 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Minireviews |
| Article Title |
Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goals
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Earl B Ettienne, Emilio Russo, Pasquale Striano, Jane M Grant-Kels and Klaus Rose |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Klaus Rose, MD, MSc, CEO, Doctor, Doctor, Klausrose Consulting, Pediatric Drug Development and More, Medical Science, Äussere Baselstrasse 308, Riehen CH-4125, Switzerland. klaus.rose@klausrose.net |
| Key Words |
Epilepsy; Pediatric drug development; Therapeutic orphans; Antiseizure medications; Pediatric investigation plan; Clinical pharmacology |
| Core Tip |
For young people with epilepsy, the framework of drug development has stalled. The misconception emerged that for people < 18 years drugs, including antiseizure medications (ASMs), need separate proof of efficacy and safety, overall called “pediatric drug development”. For ASMs, the authorities require "extrapolation of efficacy," as if minors were another species. Relevant parts of pediatric epilepsy research were pointless, and research on meaningful goals was hampered. ASMs work also before the 18th birthday. We should learn to prevent brain damage in young patients by preventing seizures and by optimize ASMs’ use. |
| Publish Date |
2024-06-14 09:10 |
| Citation |
<p>Ettienne EB, Russo E, Striano P, Grant-Kels JM, Rose K. Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goals. <i>World J Methodol</i> 2024; 14(2): 92371</p> |
| URL |
https://www.wjgnet.com/2222-0682/full/v14/i2/92371.htm |
| DOI |
https://dx.doi.org/10.5662/wjm.v14.i2.92371 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
